
Personalized healthcare: Roche perspectives

Anssi Linnankivi, Medical Director, Roche Oy



Roche in brief

Over 120 years of work to fight serious diseases

#1 In biotechnology,
oncology and
hospital products

94 000



Employees globally, **150** in Finland

Founded
1896
in Switzerland



137 million



Patients treated with
Roche products in 2017

9 billion

Euros invested in R&D in 2017



Present in over

100

countries



Roche in Finland

35 years of nationwide operations in Finland with our headquarters in Espoo

In Finland since 1982

Active in every hospital district

Market leader in hospital medicines

91,000 patients treated with Roche medicines in 2017*

Market leader in in-vitro diagnostics


5 million lab tests performed in 2017*

Pharmaceuticals and diagnostics

A unique combination of complimentary operations

Strong local medical expertise


An extensive local medical affairs team



* Internal Roche Oy statistics


Roche's R&D investment

Roche has one of the biggest Research & Development budgets globally




Focus areas of Roche

Frontrunner in several therapy areas




Traditional treatment model

One size fits all



Personalized medicine 1.0

Using biomarker diagnostics for treatment targeting and improving prognosis



From personalized to individualized treatment selection



Past – Personalized medicine 1.0



Increased knowledge on cancer biology



New diagnostic methods



Big data




AI, machine learning



Biobanks



Future – Personalized medicine 2.0



Doing now what patients need next